Partner Antoinette Konski was quoted in an FDA Week article on March 13, 2014 titled, “Gene Patent Experts Disagree About Patent Office’s Post-Myriad Guide.” The article discusses how experts are split on new guidance from the U.S. Patent and Trademark Office outlining when products that use naturally occurring genetic materials are patentable following a Supreme Court decision invalidating patents on naturally occurring DNA. Konski was quoted saying, “The guidance does not provide clear examples of marked differences that relate to current technology.”
People
Related News
June 26, 2025
In the News
Alejandro Gomez-Strozzi on Mexico-US Auto Parts Trade – 'Going forward, there is nothing but integration'
Foley & Lardner lLP partner Alejandro Gómez-Strozzi shared insights on foreign direct investment around Mexico's automotive parts sector in the El Economista article, "Efecto Trump pega más a IED en autopartes que en autos y camiones."
June 25, 2025
In the News
Jocelyn Lavallo Explores Nuclear's Emerging Role in Project Finance
Foley & Lardner LLP partner Jocelyn Lavallo examined the increasing relevance of advanced nuclear technologies in the evolving clean energy landscape in her Environment+Energy Leader article, "Nuclear’s Emerging Role in Project Finance: A Cross-Technology Perspective."
June 25, 2025
In the News
Kyle Faget Comments on AI, User Fees Ahead of MDUFA Negotiations
Foley & Lardner LLP partner Kyle Faget weighed in on the role of user fees and artificial intelligence as stakeholders prepare for the next Medical Device User Fee Amendments (MDUFA) reauthorization in the Medtech Insight article, "Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?"